Slide 1: Welcome to the 3Q24 webinar
Welcome to the 3Q24 webinar October 21, 2024
Slide 2: Today's agenda
Today’s agenda ▪ 3Q24 in brief ▪ Highlights of the Q3 ▪ R&D pipeline progress ▪ Implementation of the strategy ▪ Outlook ▪ Summary ▪ Q&A
Slide 3: Ocular oncologists
Dr. Caroline Craven, Ocular Dr. Jasmin Frances, Ocular Oncologist, Dr. Jessie Berry, Ocular oncologist, Oncologist, John A. Moran Eye Center, MSKCC, New York, NY USC, Los Angeles, CA Salt Lake City, UT
Slide 4: We fight cancer with science and technology
This is Modulight We fight cancer with science and technology ▪ We are a biomedical company ▪ We also manufacture products that designs and manufactures for other high-value applications laser devices for the treatment such as flow cytometry, quantum of cancer and eye diseases and computing and digi
Slide 5: Q3 in brief
Q3 in brief ▪ Implementation of the PPT business progressed – installations accelerated & expanded to Australia ▪ The R&D pipeline remained at 30 (27) ▪ Projects are about commercializing our own product with customer treatments and solutions ▪ The main focus in the third quarter was on current proj
Slide 6: Financial highlights July–September 2024
Financial highlights July–September 2024 ▪ Both operating cash flow -622 (- 1,738) & net cash flow -2,030 (- 4,340) significantly improved YoY ▪ Revenue was 58% more than in the corresponding period of 2023 and 34% less than in the previous quarter Revenue EBITDA EBIT ▪ The transition to the PPT bus
Slide 7: Financial highlights January–September 2024
Financial highlights January–September 2024 Revenue EBITDA EBIT ▪ Revenue was EUR 2,664 (3,006) thousand ▪ EBITDA was EUR -3,813 (-5,547) thousand EUR EUR EUR ▪ EBIT was EUR -6,134 (-7,072) thousand ▪ Operating cash flow was 2,664 -3,813 -6,134 ▪ EUR -1,644 (-5,450) Net cash flow was EUR -6,592 (-15
Slide 8: Key figures
Key figures Group EUR 1,000 unless otherwise noted 7-9/2024 7-9/2023 1–9/2024 1–9/2023 1–12/20231) Revenue 640 406 2,664 3,006 4,025 EBITDA -1,278 -2,537 -3,813 -5,547 -8,539 EBITDA, % of revenue -199.6 % -624.8% -143.1 % -184.5% -212.1% Operating result (EBIT) -2,108 -3,074 -6,134 -7,072 -12,132 Op
Slide 9: Growth in the R&D pipeline
Growth in the R&D pipeline ▪ R&D pipeline remained at 30 (27) projects – aim in all projects is to commercialize our own products Number of projects with commercialization potential ▪ Focused on advancing especially 35 the projects currently in P3 trials – good customer feedback received 30 ▪ Succes
Slide 10: Modulight's customer base
Modulight’s customer base Customer maturity Customer ownership continues to improve 35 30 ▪ 37% have over 1bn revenue 25 ▪ 60% of customers are listed companies 20 ▪ 57% are established 15 companies 10 ▪ 33% are privately owned 5 ▪ 7% are research companies 0 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23
Slide 11: Revenue model
Revenue model The objective is revenue, based on the Customized R&D projects based on the Best Efforts share of pharmaceutical or Pay Per principle, without revenue risk for Modulight Treatment fees, or the utilization rate of industrial applications. Predictability of Modulight’s revenue is improvi
Slide 12: Strategy and targets
Strategy and targets Geographical expansion Extension of the offering to new indications and applications New business models Commercial and operational excellence State-of-the-art laser technology expertise
Slide 13: Geographical expansion
Geographical expansion ▪ Investments in geographical expansion continued and has resulted in increased Modulight seeks growth business in US especially in the US market, where the company is ▪ Presence in the US market is strengthening setting up presence with with both local sales and clinical supp
Slide 14: New business models
New business models ▪ The implementation of the pay per treatment (PPT) business model progressed ▪ Install base expanded to new Modulight strongly seeks customers and continent growth through SaaS-based business models, such as ▪ Extended use across customers during the the Pay Per Treatment third
Slide 15: New indications and applications
New indications and applications ▪ More customers & leads with synergies to existing customers & indications Modulight aims to expand ▪ A very high-profile quantum company its offering to cover other indications as well as ordered a product based on our unique laser extend the use of its technology
Slide 16: Commercial and operational excellence
Commercial and operational excellence ▪ Focus on operational efficiency improved operating margins Modulight aims to develop ▪ Strategic distribution its commercial and partnerships developed and operational expertise as well as the ESG, governance resulted in new customers in and reporting capabili
Slide 17: State-of-the-art laser technology expertise
State-of-the-art laser technology expertise ▪ The major investment program has been completed and shows on net cash flow as big one-time costs Modulight continues investments into high value related to take in use the equipment are reducing add laser technology to ▪ Taking new technologies into use
Slide 18: Outlook
Outlook Most of Modulight's customer projects are various types in the early stages of development. In line with its strategy, Modulight is transitioning from a payment model based on device deliveries to one focused on treatment sessions (PPT business model). The progress of individual projects is
Slide 19: Summary
Summary ▪ R&D pipeline at 30 projects and focus to more mature projects ▪ New customers with potential for pipeline expansion as projects mature ▪ Both operating cash flow -622 (-1,738) & net cash flow -2,030 (-4,340) significantly improved YoY ▪ PPT model implementation progressing – new customers
Slide 20: Thank you! Questions?
Thank you! Questions?